2 Biotech Stocks With Major Incoming Catalysts

The end of the first quarter is just a few weeks away and more than a few biotechs still haven't delivered the important clinical trial results they told investors to expect before the end of the period. The clock's ticking for Axsome Therapeutics (NASDAQ: AXSM), Galapagos (NASDAQ: GLPG) and their experimental treatments.